Syncom Formulations Share Price Target
About Syncom Formulation :
Syncom Formulations (India) Ltd. became included within the 12 months 1988. Its state-of-the-art share charge is 9.eight. Its modern-day market capitalisation stands at Rs 817.five Cr. in the today’s region, corporation has reported Gross income of Rs. 2448.05 Cr and general earnings of Rs.2519.46 Cr. The organisation‘s control includes Shubham Dubey, Praveen Jindal, Vinod Kumar Kabra, Krishna Das Neema, Rinki Bankda, Vijay Shankarlal Bankda, Kedarmal Bankda.
it’s far indexed at the BSE with a BSE Code of 524470 , NSE with an NSE symbol of and ISIN of INE312C01025. it’s Registered office is at 7 Niraj business property,Off Mahakali Caves street,Andheri (E)Mumbai-400093, Maharashtra. Their Registrars are ACC Ltd. it’s auditors are Sanjay Mehta & associates, SP Moondra & Co
https://web.archive.org/web/20220528074817if_/https://googleads.g.doubleclick.net/pagead/ads?client=ca-pub-4279883293592163&output=html&h=178&slotname=4829626054&adk=450484092&adf=703191480&pi=t.ma~as.4829626054&w=712&fwrn=4&lmt=1672990845&rafmt=11&psa=0&format=712×178&url=https%3A%2F%2Fsharepricetarget.net%2Fsyncom-formulations-share-price-target-2022-2023-2025-2030%2F&wgl=1&uach=WyJXaW5kb3dzIiwiMTUuMC4wIiwieDg2IiwiIiwiMTA4LjAuNTM1OS4xMjUiLFtdLG51bGwsbnVsbCwiNjQiLFtbIk5vdD9BX0JyYW5kIiwiOC4wLjAuMCJdLFsiQ2hyb21pdW0iLCIxMDguMC41MzU5LjEyNSJdLFsiR29vZ2xlIENocm9tZSIsIjEwOC4wLjUzNTkuMTI1Il1dLGZhbHNlXQ..&dt=1653724109171&bpp=2&bdt=12760&idt=7374&shv=r20220601&mjsv=m202205310101&ptt=9&saldr=aa&abxe=1&prev_fmts=0x0%2C304x250&nras=1&correlator=4857345246973&frm=20&pv=1&ga_vid=757274588.1653724117&ga_sid=1653724117&ga_hid=912045363&ga_fc=1&rplot=4&u_tz=0&u_his=4&u_h=768&u_w=1366&u_ah=720&u_aw=1366&u_cd=24&u_sd=1&dmc=8&adx=120&ady=1214&biw=1349&bih=617&scr_x=0&scr_y=0&eid=44759875%2C44759926%2C44759842%2C31065545&oid=2&pvsid=1735028745331966&pem=278&tmod=1699698271&uas=0&nvt=1&eae=0&fc=1920&brdim=0%2C0%2C0%2C0%2C1366%2C0%2C1366%2C720%2C1366%2C617&vis=1&rsz=%7C%7CpeEbr%7C&abl=CS&pfx=0&fu=128&bc=31&ifi=2&uci=a!2&btvi=1&fsb=1&xpc=xBtjyxDc5V&p=https%3A//web.archive.org&dtd=M
| Mkt cap | 807.54Cr |
| 52-wk high | 13.55 |
| 52-wk low | 2.28 |
| P/E ratio | 28.85 |
| Div yield | – |
Share Target Price 2022 2023 2025 2030 of syncom formulations
Show 102550100 entriesSearch:
| Year | Min | Max |
|---|---|---|
| 2022 | 10.11 | 13.24 |
| 2023 | 14.57 | 17.32 |
| 2024 | 15.65 | 19.24 |
| 2025 | 27.39 | 39.21 |
| 2026 | 36.14 | 45.32 |
| 2027 | 42.88 | 52.25 |
| 2028 | 56 | 67 |
| 2029 | 72 | 93 |
| 2030 | 88 | 112 |
Showing 1 to 9 of 9 entries
Syncom Formulation Fundamental :
Is SYNCOM FORMULATIONS (INDIA) good for long time investment?
As on 02-Dec-2021, the fundamentals of SYNCOM FORMULATIONS (INDIA) look poor and therefore it may now not be true for long time funding ! See economic performance of SYNCOM FORMULATIONS (INDIA) . Please study the alternative parameters which includes Valuation, charge Momentum, information & company Governance and/or consult an funding marketing consultant earlier than taking an funding decision!
Is SYNCOM FORMULATIONS (INDIA) UnderValued or overrated?
As on 02-Dec-2021, SYNCOM FORMULATIONS (INDIA) is Over Valued based on the estimates of intrinsic cost and for this reason might not be a good buying possibility according to proportion Valuation at this time!
what’s the Intrinsic value of SYNCOM FORMULATIONS (INDIA) ?
As on 02-Dec-2021, the Intrinsic cost of SYNCOM FORMULATIONS (INDIA) is Rs. 2.seventy four decided based totally on Median of the 3 historical fashions.
fair cost [Median EV / EBIDTA Model] : Rs. 1.05
honest price [Median EV / Sales Model] : Rs. three.08
truthful fee [Median Price / Sales Model] : Rs. 2.seventy four
Median truthful fee of SYNCOM FORMULATIONS (INDIA) : Rs. 2.seventy four
Is SYNCOM FORMULATIONS (INDIA) buying and selling at a top class or cut price?
As on 02-Dec-2021, SYNCOM FORMULATIONS (INDIA) is trading at a top rate of 252% based at the estimates of Median Intrinsic fee!
https://web.archive.org/web/20220528074817if_/https://googleads.g.doubleclick.net/pagead/ads?client=ca-pub-4279883293592163&output=html&h=178&slotname=4829626054&adk=450484092&adf=1118777481&pi=t.ma~as.4829626054&w=712&fwrn=4&lmt=1672990986&rafmt=11&psa=0&format=712×178&url=https%3A%2F%2Fsharepricetarget.net%2Fsyncom-formulations-share-price-target-2022-2023-2025-2030%2F&wgl=1&uach=WyJXaW5kb3dzIiwiMTUuMC4wIiwieDg2IiwiIiwiMTA4LjAuNTM1OS4xMjUiLFtdLG51bGwsbnVsbCwiNjQiLFtbIk5vdD9BX0JyYW5kIiwiOC4wLjAuMCJdLFsiQ2hyb21pdW0iLCIxMDguMC41MzU5LjEyNSJdLFsiR29vZ2xlIENocm9tZSIsIjEwOC4wLjUzNTkuMTI1Il1dLGZhbHNlXQ..&dt=1653724109173&bpp=2&bdt=12762&idt=7373&shv=r20220601&mjsv=m202205310101&ptt=9&saldr=aa&abxe=1&prev_fmts=0x0%2C304x250%2C712x178%2C304x250&nras=1&correlator=4857345246973&frm=20&pv=1&ga_vid=757274588.1653724117&ga_sid=1653724117&ga_hid=912045363&ga_fc=1&rplot=4&u_tz=0&u_his=4&u_h=768&u_w=1366&u_ah=720&u_aw=1366&u_cd=24&u_sd=1&dmc=8&adx=120&ady=3875&biw=1349&bih=617&scr_x=0&scr_y=1462&eid=44759875%2C44759926%2C44759842%2C31065545&oid=2&pvsid=1735028745331966&pem=278&tmod=1699698271&uas=3&nvt=1&eae=0&fc=1920&brdim=0%2C0%2C0%2C0%2C1366%2C0%2C1366%2C720%2C1366%2C617&vis=1&rsz=%7C%7CpeEbr%7C&abl=CS&pfx=0&fu=128&bc=31&ifi=3&uci=a!3&btvi=3&fsb=1&xpc=cQeYjFS4cl&p=https%3A//web.archive.org&dtd=M
definitely. See the basics, it’s far in profit for decades and giving dividend constantly for numerous years. however, the dividend quantity could be very nominal but it proves the promoters’ sincerity toward the shareholders. study its commercial enterprise version from their internet site. It is not best a pharma business enterprise however manufactures and trades with some medical disposable materials. So, sooner or later it will come up to above 20/-. Is it not a multibagger?
TAGs